212 related articles for article (PubMed ID: 21996981)
1. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
Ganzemueller J; Hartmann B; Keller F; Stracke S
Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
[TBL] [Abstract][Full Text] [Related]
4. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.
Chung BH; Yun JT; Ha SE; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
Transpl Infect Dis; 2013 Dec; 15(6):559-68. PubMed ID: 24011062
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
6. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
7. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report.
Grenda R; Jarmużek W; Piątosa B; Rubik J
Pediatr Transplant; 2011 Sep; 15(6):E121-5. PubMed ID: 20331516
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
Tsagalis G; Psimenou E; Nakopoulou L; Laggouranis A
Artif Organs; 2011 Apr; 35(4):420-5. PubMed ID: 20637013
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
13. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
16. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
17. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
[TBL] [Abstract][Full Text] [Related]
19. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.
Dęborska-Materkowska D; Kozińska-Przybył O; Mikaszewska-Sokolewicz M; Durlik M
Transplant Proc; 2014 Oct; 46(8):2908-11. PubMed ID: 25380948
[TBL] [Abstract][Full Text] [Related]
20. Isoagglutinin adsorption in ABO-incompatible transplantation.
Genberg H; Kumlien G; Wennberg L; Tydén G
Transfus Apher Sci; 2010 Oct; 43(2):231-5. PubMed ID: 20667787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
